Research on the live, attenuated Mycobacterium TB vaccine, MTBVAC, in South African infants, appeared in The Lancet Respiratory Medicine journal this week.
This Phase 1b study, conducted in a TB endemic community, showed that vaccination of infants with MTBVAC displayed a similar safety profile and had indistinguishable reactions at the injection site to that of the current licensed TB vaccine, Bacille Calmette-Guérin (BCG), which has an excellent safety record.
Vaccination with MTBVAC induced a long-lasting immune response of greater magnitude than that of BCG at a comparable dose. This promising data supports further progression of MTBVAC through ongoing Phase 2a dose-defining studies and into large-scale infant efficacy trials.
Satvi director Professor Mark Hatherill said: “These exciting results are an important step towards a more effective TB vaccine, and support plans for a much larger trial to better define the safety and efficacy of MTBVAC in infants living in TB endemic countries.”
Satvi immunology deputy director Professor Tom Scriba explained the results from this trial showed that MTBVAC was capable of inducing robust and durable immune responses and trigger the next stage of evaluation for this vaccine candidate.
According to Biofabri general manager Esteban Rodríguez, in 2008, Biofabri acquired the c ommitment to make available the MTBVAC vaccine worldwide at an affordable price.
Such a commitment enhances Biofabri’s involvement in the fight against TB, particularly in low income countries.
Carlos Martin of the University of Zaragoza said the next step was to demonstrate the efficacy of MTBVAC in TB endemic countries.
“The sooner we can show the efficacy of MTBVAC in clinical trials, the earlier MTBVAC could help us save millions of lives,” Martin said.
Jelle Thole of TBVI said a new vaccine against TB was urgently needed for all age groups.